Search results for "Phase 3 trial"

Daewoong Pharmaceutical Nears Completion of Phase 2 IPF Trial for Bersiporosin, Readout Set for H1 2027

Daewoong Pharmaceutical Nears Completion of Phase 2 IPF Trial for Bersiporosin, Readout Set for H1 2027

Daewoong Pharmaceutical has completed patient enrollment for the global Phase 2 clinical trial of bersiporosin (DWN12088), its first-in-class...
GC Pharma’s Homegrown mRNA Vaccine Advances to Phase 2 Trials

GC Pharma’s Homegrown mRNA Vaccine Advances to Phase 2 Trials

GC Pharma announced on the 11th that South Korea’s Ministry of Food and Drug Safety has approved its Phase 2 clinical trial application for its...
Hanmi Completes Key Phase 2 Dosing for Once-Weekly Rare Disease Drug Efpeglucagon

Hanmi Completes Key Phase 2 Dosing for Once-Weekly Rare Disease Drug Efpeglucagon

During normal digestion, dietary carbohydrates convert into glucose that circulates in the blood.
JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide

JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide

JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s...
VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial

VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial

Otsuka Pharmaceutical’s VOYXACT (active ingredient: sibeprenlimab) demonstrated long-term kidney protection by...
Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy

Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy

CKD-339, an essential hypertension treatment under development by Chong Kun Dang, is advancing into a Phase 3 clinical...
Placebo Outperforms TG-C: Data Errors and Stock Volatility Cloud Kolon TissueGene’s Phase 3 Trial

Placebo Outperforms TG-C: Data Errors and Stock Volatility Cloud Kolon TissueGene’s Phase 3 Trial

Kolon TissueGene’s knee osteoarthritis cell and gene therapy, TG-C, has failed to achieve statistical significance on...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data

HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data

HLB Innovation announced on July 23 that its U.S. subsidiary, Verismo Therapeutics, has expanded the Phase 1 clinical...
Fast-Tracking Biosimilars: South Korea to Waive Phase 3 Clinical Trials Under New Guidelines

Fast-Tracking Biosimilars: South Korea to Waive Phase 3 Clinical Trials Under New Guidelines

South Korean regulators have revised requirements to significantly reduce the time and financial burden of biosimilar...